外阴癌市场 - 全球产业规模、份额、趋势、机会及预测（按癌症类型、治疗类型、最终用户、地区和竞争格局划分，2021-2031年）

全球外阴癌市场预计将从 2025 年的 6.5078 亿美元成长到 2031 年的 9.4052 亿美元，复合年增长率为 6.33%。

该市场涵盖用于治疗外阴恶性肿瘤的诊断技术和治疗性介入，例如手术、化疗和免疫调节剂。推动这一市场成长的关键因素包括老年女性人口的增加（她们患有外阴肿瘤的风险更高）以及人类乳突病毒 (HPV) 感染率的上升（HPV 是鳞状细胞癌的主要病因）。此外，政府大力推行的旨在促进女性健康的计划提高了早期发现率，从而增加了需要及时治疗的患者数量。

然而，由于先进生物疗法的高成本以及根治性手术带来的严重副作用等因素，市场面临许多障碍。这些经济和临床方面的障碍可能会阻碍患者继续治疗，并限制医疗预算有限的开发中国家的市场扩张。根据美国癌症协会预测，2025年美国预计将新增约7,480个例外阴癌病例。这一数字表明，外阴癌仍然是一个沉重的疾病负担，并凸显了製药企业需要致力于研发更具成本效益且耐受性良好的创新治疗方法。

市场驱动因素

全球外阴癌市场正因一系列新型免疫疗法和标靶治疗的涌现而显着变化，为进行性或復发性疾病患者带来了新的希望。製药开发商正优先研发免疫查核点抑制剂，以克服传统放射线治疗的局限性，并提高复杂病例的疗效。例如，在2025年6月发表于《靶向肿瘤学》（Targeted Oncology）杂誌的一篇题为「Pembrolizumab联合治疗不可切除外阴癌前景可观」的报导中，报道了一项针对进行性不可切除鳞状细胞癌患者的II期临床试验，该试验采用Pembrolizumab、Cisplatin和放射线治疗有效生物製药的不断涌现，透过扩大患者群体和促进高附加价值治疗方法的采用，正在推动市场成长。

同时，人类乳突病毒（HPV）感染率的上升趋势成为市场扩张的主要驱动力，也催生了对更完善的预防和治疗策略的需求。由于感染率居高不下，尤其是在年轻人中，HPV相关恶性肿瘤的增加持续推动着对专业肿瘤护理的需求。美国疾病管制与预防中心（CDC）在其2025年12月发布的报告《人类乳突病毒相关癌症》中指出，据估计，HPV目前约占所有外阴癌病例的69%。这种强烈的因果关係凸显了进行针对性干预和严格筛检计画的迫切性。此外，美国癌症协会估计，2025年美国将有1,770名女性死于外阴癌，这更强调了持续开发先进的诊断和治疗方案的重要性。

市场挑战

生物疗法的高昂成本是全球外阴癌市场扩张的主要障碍。这些药物的高价结构造成了巨大的经济壁垒，尤其是在医疗预算有限的发展中地区。当先进的治疗方法仍然难以负担时，市场渗透率就会受到严重阻碍，製造商也无法在这些地区实现最大化收益。因此，该市场未能广泛普及，成长主要局限于富裕人群，而无法满足更广泛的全球患者群体的需求。

这种经济限制因素因根治性手术相关的临床障碍而进一步加剧，这些手术往往伴随严重的副作用风险。这些因素共同导致疾病盛行率与现有治疗性介入的利用率之间存在脱节。死亡率数据凸显了这种差距，显示目前的市场机制不足以减轻疾病负担。根据美国癌症协会预测，到2025年，外阴癌预计将在美国造成约1,770例死亡。这项统计数据表明，儘管技术已经成熟，但经济和临床障碍仍然阻碍着治疗的成功，并直接抑制了市场成长。

市场趋势

全球外阴癌市场在哨兵淋巴结（SLN）定位和切片检查通讯协定取得了显着进展，正从传统的染料标记技术过渡到萤光引导技术，从而减少手术併发症。临床医生越来越多地采用靛氰绿（ICG）示踪剂来提高淋巴结分期的准确性，从而最大限度地减少与淋巴结清除术相关的淋巴水肿的发生率。这一转变得到了令人信服的临床数据的支持。根据发表在2025年5月《医师周刊》（Physician's Weekly）上的报导“靛氰绿在外阴SLN检测中与双重示踪剂效果相当”，一项系统评价发现，使用靛氰绿进行哨兵淋巴结检测的患者检出率高达88%，证明其是一种高效且创伤性更小的标准标准。

同时，基因组分析在个人化治疗方案製定中的应用正在重塑治疗格局，尤其是在HPV非依赖性肿瘤领域，这类肿瘤历来缺乏标靶治疗方案。临床医生正将次世代定序纳入常规诊断流程，以识别具有治疗价值的体细胞突变，并促进患者分层，从而为新兴的精准医疗疗法提供依据。这一趋势也得到了近期分子特征分析研究的支持。根据发表于2024年12月《国际妇科肿瘤学杂誌》（International Journal of Gynecological Cancer）的一篇题为“人类乳头瘤病毒非依赖性外阴浸润性鳞状细胞癌的分子和微环境特征”的论文，靶向定序发现，在68%的研究病例中存在影响TP53的復发性生物标誌物治疗了显性生物标誌物的重要潜力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球外阴癌市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 癌症类型（外阴鳞状细胞癌、外阴黑色素瘤、腺癌、基底细胞癌）
  • 依治疗方法（化疗、手术、雷射手术、切除术、外阴阴道分离、根治性外阴切除术、放射性外阴切除术、生物治疗）
  • 依最终使用者（医院/诊所、研究/学术机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美外阴癌市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲外阴癌市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区外阴癌市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲外阴癌市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲外阴癌市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球外阴癌市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Merck & Co. Inc.
• Sanofi SA
• Novartis AG
• Astellas Pharma Inc.
• Pfizer Inc.
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Vulvar Cancer Market is projected to increase from USD 650.78 Million in 2025 to USD 940.52 Million by 2031, registering a CAGR of 6.33%. This market comprises diagnostic technologies and therapeutic interventions, such as surgery, chemotherapy, and immunomodulators, designed to manage vulvar malignancies. Key factors driving this growth include an aging female population increasingly prone to vulvar neoplasia and a rising incidence of Human Papillomavirus infections, which are a primary cause of squamous cell carcinomas. Additionally, strong government programs focused on improving women's health are boosting early detection rates, thereby increasing the number of patients requiring timely medical treatment.

However, the market faces significant hurdles due to the high cost of advanced biologic therapies and the severe side effects often associated with radical surgical procedures. These financial and clinical barriers can discourage patient compliance and restrict market reach in developing nations with limited healthcare budgets. According to the American Cancer Society, approximately 7,480 new cases of vulvar cancer are expected to be diagnosed in the United States in 2025. This figure highlights the persistent burden of the disease, underscoring the need for manufacturers to focus on developing cost-effective and well-tolerated treatment innovations.

Market Driver

The Global Vulvar Cancer Market is being significantly transformed by a strong pipeline of novel immunotherapies and targeted agents, providing new prospects for patients with advanced or recurrent conditions. Pharmaceutical developers are prioritizing immune checkpoint inhibitors to surpass the limitations of traditional chemoradiation, thereby improving efficacy for complex cases. For example, Targeted Oncology reported in June 2025, in the article 'Pembrolizumab Combo Promising for Unresectable Vulvar Cancer', that a recent phase 2 clinical trial showed a 75% objective response rate in patients with locally advanced, unresectable squamous cell carcinoma when treated with a combination of pembrolizumab, cisplatin, and radiation. This rise in effective biologic agents is fueling market growth by widening the eligible patient base and promoting the adoption of premium therapeutic regimens.

Simultaneously, the increasing prevalence of Human Papillomavirus (HPV) infections acts as a major catalyst for market expansion, creating a need for improved preventative and therapeutic strategies. As infection rates endure, particularly among younger populations, the rise in HPV-linked malignancies continues to elevate the demand for specialized oncological care. The Centers for Disease Control and Prevention (CDC) noted in its December 2025 report 'Cancers Associated with Human Papillomavirus' that HPV is now estimated to cause approximately 69% of all vulvar cancers. This strong causal link emphasizes the urgent need for targeted interventions and strict screening programs; furthermore, the American Cancer Society estimates that 1,770 women in the United States will die from vulvar cancer in 2025, reinforcing the critical necessity for the continued development of advanced diagnostic and therapeutic solutions.

Market Challenge

The prohibitive costs associated with biologic therapies represent a major barrier to the expansion of the Global Vulvar Cancer Market. The high pricing structures of these agents create substantial economic obstacles, particularly in developing regions where healthcare budgets are constrained. When advanced treatments remain financially inaccessible, market penetration is severely curtailed, preventing manufacturers from optimizing revenue within these demographics. Consequently, the market struggles to achieve broad adoption, limiting its growth primarily to affluent segments rather than addressing the needs of the wider global patient population.

This economic restriction is compounded by clinical deterrents associated with radical surgical procedures, which frequently carry risks of severe side effects. Collectively, these factors create a gap between the prevalence of the disease and the utilization of available therapeutic interventions. This disparity is underscored by mortality data suggesting that current market mechanisms are not fully alleviating the disease burden. According to the American Cancer Society, approximately 1,770 deaths were projected to result from vulvar cancer in the United States in 2025. This statistic indicates that despite available technologies, economic and clinical hurdles continue to impede the successful delivery of care, directly hampering market growth.

Market Trends

The Global Vulvar Cancer Market is experiencing significant advancement in sentinel lymph node (SLN) mapping and biopsy protocols, shifting from traditional dye-based methods to fluorescence-guided techniques that reduce surgical morbidity. Clinicians are increasingly adopting indocyanine green (ICG) tracers to enhance the precision of nodal staging, thereby minimizing the incidence of lymphedema associated with complete lymphadenectomy. This transition is supported by compelling clinical data; according to Physician's Weekly in May 2025, in the article 'Indocyanine Green Matches Dual Tracers in Vulvar SLN Detection', a systematic review found that the per-patient sentinel lymph node detection rate for indocyanine green was 88%, proving it to be a highly effective and less invasive alternative to standard radiotracers.

Concurrently, the implementation of genomic profiling for personalized treatment plans is reshaping the therapeutic landscape, particularly for HPV-independent tumors which have historically lacked targeted options. Medical centers are incorporating next-generation sequencing into routine diagnostic workflows to identify actionable somatic mutations, facilitating the stratification of patients for emerging precision medicine therapies. This trend is substantiated by recent molecular characterization efforts; as reported by the International Journal of Gynecological Cancer in December 2024, in the article 'Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva', targeted sequencing revealed recurrent somatic mutations affecting TP53 in 68% of the studied cases, highlighting its potential as a critical biomarker for therapeutic selection.

Key Market Players

• Merck & Co. Inc.
• Sanofi SA
• Novartis AG
• Astellas Pharma Inc.
• Pfizer Inc.
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company

Report Scope

In this report, the Global Vulvar Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvar Cancer Market, By Cancer Type

• Vulvar Squamous Cell Carcinoma
• Vulvar Melanoma
• Adenocarcinoma
• Basal Cell Carcinoma

Vulvar Cancer Market, By Treatment Type

• Chemotherapy
• Surgery
• Laser Surgery
• Excision
• Skinning Vulvectomy
• Radical Vulvectomy
• Radiation Vulvectomy
• Biologic Therapy

Vulvar Cancer Market, By End-User

• Hospitals & Clinics
• Research & Academic Institutes
• Others

Vulvar Cancer Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vulvar Cancer Market.

Available Customizations:

Global Vulvar Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Vulvar Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma)
  • 5.2.2. By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic Therapy)
  • 5.2.3. By End-User (Hospitals & Clinics, Research & Academic Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Vulvar Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Vulvar Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Vulvar Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Vulvar Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By End-User

7. Europe Vulvar Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Vulvar Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Vulvar Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Vulvar Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Vulvar Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Vulvar Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By End-User

8. Asia Pacific Vulvar Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Vulvar Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Vulvar Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Vulvar Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Vulvar Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Vulvar Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Vulvar Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Vulvar Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Vulvar Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Vulvar Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By End-User

10. South America Vulvar Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Vulvar Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Vulvar Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Vulvar Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Vulvar Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck & Co. Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi SA
• 15.3. Novartis AG
• 15.4. Astellas Pharma Inc.
• 15.5. Pfizer Inc.
• 15.6. Abbott Laboratories
• 15.7. Bristol-Myers Squibb Company
• 15.8. Takeda Pharmaceutical Company Limited
• 15.9. F. Hoffmann-La Roche Ltd
• 15.10. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer